AVALO THERAPEUT. DL-,001 C6K0.F Stock
AVALO THERAPEUT. DL-,001 Price Chart
AVALO THERAPEUT. DL-,001 C6K0.F Financial and Trading Overview
AVALO THERAPEUT. DL-,001 stock price | 9.86 EUR |
Previous Close | 0.39 EUR |
Open | 0.53 EUR |
Bid | 0 EUR x N/A |
Ask | 0 EUR x N/A |
Day's Range | 0.39 - 0.53 EUR |
52 Week Range | 0.39 - 32.23 EUR |
Volume | 100 EUR |
Avg. Volume | 1 EUR |
Market Cap | 44.75M EUR |
Beta (5Y Monthly) | 1.746275 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.4 EUR |
C6K0.F Valuation Measures
Enterprise Value | 527.76M EUR |
Trailing P/E | N/A |
Forward P/E | -0.56811595 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 7.3380113 |
Price/Book (mrq) | 1.0919219 |
Enterprise Value/Revenue | 86.547 |
Enterprise Value/EBITDA | -8.294 |
Trading Information
AVALO THERAPEUT. DL-,001 Stock Price History
Beta (5Y Monthly) | 1.746275 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 32.23 EUR |
52 Week Low | 0.39 EUR |
50-Day Moving Average | 4.61 EUR |
200-Day Moving Average | 10.87 EUR |
C6K0.F Share Statistics
Avg. Volume (3 month) | 1 EUR |
Avg. Daily Volume (10-Days) | 1 EUR |
Shares Outstanding | 112.32M |
Float | 38.86M |
Short Ratio | N/A |
% Held by Insiders | N/A |
% Held by Institutions | N/A |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | N/A |
Trailing Annual Dividend Yield | N/A |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2021 |
Most Recent Quarter (mrq) | March 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1064.39% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -64.78% |
Return on Equity (ttm) | -383.94% |
Income Statement
Revenue (ttm) | 6.1M EUR |
Revenue Per Share (ttm) | 0.06 EUR |
Quarterly Revenue Growth (yoy) | 148.00% |
Gross Profit (ttm) | -44721000 EUR |
EBITDA | -63634000 EUR |
Net Income Avi to Common (ttm) | -75826000 EUR |
Diluted EPS (ttm) | -0.765 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 38.47M EUR |
Total Cash Per Share (mrq) | 0.34 EUR |
Total Debt (mrq) | 35.65M EUR |
Total Debt/Equity (mrq) | 562.04 EUR |
Current Ratio (mrq) | 2.44 |
Book Value Per Share (mrq) | 0.359 |
Cash Flow Statement
Operating Cash Flow (ttm) | -68643000 EUR |
Levered Free Cash Flow (ttm) | -34459500 EUR |
Profile of AVALO THERAPEUT. DL-,001
Country | Germany |
State | MD |
City | Rockville |
Address | 540 Gaither Road |
ZIP | 20850 |
Phone | 410 522 8707 |
Website | https://www.avalotx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 42 |
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Q&A For AVALO THERAPEUT. DL-,001 Stock
What is a current C6K0.F stock price?
AVALO THERAPEUT. DL-,001 C6K0.F stock price today per share is 9.86 EUR.
How to purchase AVALO THERAPEUT. DL-,001 stock?
You can buy C6K0.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AVALO THERAPEUT. DL-,001?
The stock symbol or ticker of AVALO THERAPEUT. DL-,001 is C6K0.F.
Which industry does the AVALO THERAPEUT. DL-,001 company belong to?
The AVALO THERAPEUT. DL-,001 industry is Biotechnology.
How many shares does AVALO THERAPEUT. DL-,001 have in circulation?
The max supply of AVALO THERAPEUT. DL-,001 shares is 1.03M.
What is AVALO THERAPEUT. DL-,001 Price to Earnings Ratio (PE Ratio)?
AVALO THERAPEUT. DL-,001 PE Ratio is now.
What was AVALO THERAPEUT. DL-,001 earnings per share over the trailing 12 months (TTM)?
AVALO THERAPEUT. DL-,001 EPS is 0 EUR over the trailing 12 months.
Which sector does the AVALO THERAPEUT. DL-,001 company belong to?
The AVALO THERAPEUT. DL-,001 sector is Healthcare.